How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?  

I think it will be increasingly difficult to prove OS in an environment where patients should have access to highly active ADCs at progression. Positive PFS is meaningful for our patients when associated with a well-tolerated regimen that has a favorable dosing schedule and quality of life metrics.

Dato-DXd significantly reduced the risk of progressive disease or death compared to chemotherapy in patients with metastatic or inoperable HR+ HER2- breast cancer per TROPION-Breast01. It also showed an improved objective response rate and consistent benefit in improving progression-free survival ac...

Current evidence indicates that Dato-DXd demonstrates promising PFS and manageable toxicity in heavily pretreated HR+/HER2- patients, but network meta-analyses suggest it may be less effective than other antibody-drug conjugates in both PFS and OS, and its optimal role remains uncertain. There is li...